| Autor: |
Healy D; Data Based Medicine, Wales, UK., Mangin D; Department of Family Medicine, McMaster University, Hamilton, ON, Canada.; Department of General Practice, University of Otago, Christchurch, New Zealand. |
| Jazyk: |
angličtina |
| Zdroj: |
Epidemiology and psychiatric sciences [Epidemiol Psychiatr Sci] 2024 Sep 18; Vol. 33, pp. e40. Date of Electronic Publication: 2024 Sep 18. |
| DOI: |
10.1017/S2045796024000441 |
| Abstrakt: |
While sexual dysfunction is a well-known side effect of taking selective serotonin reuptake inhibitors (SSRIs), in an undetermined number of patients, sexual function does not return to pre-drug baseline after stopping SSRIs. The condition is known as post-SSRI sexual dysfunction (PSSD) and is characterised most commonly by genital numbness, pleasureless or weak orgasm, loss of libido and erectile dysfunction. This article provides a commentary on the incidence and prevalence of PSSD based on a combination of academic literature as well as clinical and research experience. A number of obstacles to quantifying the occurrence of PSSD are outlined including difficulty in designing a suitable study method. Other contextual obstacles include patient embarrassment at raising sexual concerns, the response of healthcare professionals, inability to stop an antidepressant due to withdrawal issues in a proportion of patients and patient unawareness that their sexual difficulties are linked to prior medication compounded by variability of online information and a lack of information aimed at public education. A definition of PSSD with diagnostic criteria has been published. A MedDRA code for PSSD has also been introduced, but this is yet to be adopted by regulators. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
